BrainStorm Receives US Patent Allowance for NurOwn Platform

BrainStorm Cell Therapeutics (NASDAQ:BCLI) has announced that the US Patent and Trademark Office has given a notice of allowance for its US Patent application number 15/113, 105.

As quoted in the press release:

The allowed claims cover a pharmaceutical composition for MSC-NTF cells secreting neurotrophic factors (NurOwn^®) comprising a culture medium as a carrier and an isolated population of differentiated bone marrow-derived MSCs that secrete neurotrophic factors.

Patent families protecting NurOwn^® have previously issued in the United States, Japan, Europe, Hong-Kong and Israel.

“This allowance further expands the patent protection of the NurOwn^® Cellular Therapeutic Technology Platform and enables us to accelerate clinical development for new neurodegenerative indications,” commented BrainStorm President and CEO, Chaim Lebovits.

Click here to read the full press release.